# QuarkMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/quarkmed

- Industry: Healthcare
- Headquarters: Beijing, China
- Website: www.qmcro.com
- Latest round: Series A (Oct 11, 2024)
- Investors on record: 3

## About

Based in Beijing, China, and founded in 2022, QuarkMed operates as a CRO (Contract Research Organization) service company that focuses on providing nuclear medicine clinical CRO services. The company has branches and offices in Shanghai, Guangzhou, Hangzhou, Chengdu and other regions. The general manager, Dawei Y, graduated from Tsinghua University and Indiana University. It has cooperated with Forward, Deepwise, Yunnan Baiyao, United Imaging, and other enterprises. In 2023, the company became a member of the Radiopharmaceutical Branch of the Chinese Nuclear Society. In October 2024, QuarkMed closed a series A funding.

The company's business include drug and device clinical research, data management and statistical analysis, SMO (Site Management Organization), etc. Other services include drug and device registration, clinical operations, post-marketing studies and pharmacoeconomic evaluation. Its services cover nuclear medicine, cell therapy, cardiovascular and cerebrovascular, oncology, respiratory, neuropsychiatric and other fields.

QuarkMed generates revenue by providing drug and device clinical research, data management and statistical analysis, and SMO services.

The company will continue to improve its radiopharmaceutical service chain and comprehensive clinical research capabilities.

## Funding rounds

- Series A, Oct 11, 2024 — Bohe Angel Fund, HangZhou Capital, Taikun Fund

## Investors

- Bohe Angel Fund — Series A
- HangZhou Capital (https://capitalatlas.ai/funds/hangzhou-capital) — Series A
- Taikun Fund — Series A